44. Transl Cancer Res. 2018 Feb;7(Suppl 1):S81-S84. doi: 10.21037/tcr.2018.01.07.Cost-effectiveness in managing skeletal related events in breast cancer: astrategy of less-intense dosing schedule of bone modifying agents.Tella SH(1)(2), Kommalapati A(2), Singhi RK(2).Author information: (1)National Institutes of Health (NIH), Bethesda, USA.(2)Department of Medicine, University of South Carolina School of Medicine,Columbia, SC, USA.Comment on    J Clin Oncol. 2017 Dec 10;35(35):3949-3955.DOI: 10.21037/tcr.2018.01.07 PMCID: PMC5983387PMID: 29863174 